Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Genetics
Volume 2017, Article ID 6236714, 4 pages
https://doi.org/10.1155/2017/6236714
Case Report

Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer

1College of Pharmacy, University of Florida, Gainesville, FL, USA
2School of Health Sciences, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
3Department of Clinical Genomics, Center for Individualized Medicine, Mayo Clinic, Jacksonville, FL, USA

Correspondence should be addressed to Paldeep S. Atwal; moc.liamg@lawta.peedlap

Received 14 April 2017; Revised 25 August 2017; Accepted 20 September 2017; Published 16 October 2017

Academic Editor: Balraj Mittal

Copyright © 2017 Sofia Garcia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Hardy, S. Argyropoulos, and D. J. Nutt, “Venlafaxine: a new class of antidepressant.,” Hospital medicine (London, England : 1998), vol. 63, no. 9, pp. 549–552, 2002. View at Google Scholar · View at Scopus
  2. J. Davidson, D. Baldwin, D. J. Stein et al., “Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial,” Archives of General Psychiatry, vol. 63, no. 10, pp. 1158–1165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Davidson, B. O. Rothbaum, P. Tucker, G. Asnis, I. Benattia, and J. J. Musgnung, “Venlafaxine extended release in posttraumatic stress disorder: A sertraline- and placebo-controlled study,” Journal of Clinical Psychopharmacology, vol. 26, no. 3, pp. 259–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Danjou and D. Hackett, “Safety and tolerance profile of venlafaxine,” International Clinical Psychopharmacology, vol. 10, no. 2, pp. 15–20, 1995. View at Google Scholar · View at Scopus
  5. K. Letsas, P. Korantzopoulos, L. Pappas, D. Evangelou, M. Efremidis, and F. Kardaras, “QT interval prolongation associated with venlafaxine administration,” International Journal of Cardiology, vol. 109, no. 1, pp. 116-117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Castanares-Zapatero, N. Gillard, A. Capron, V. Haufroid, and P. Hantson, “Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism,” Forensic Science International, vol. 266, pp. e48–e51, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Sangkuhl, J. C. Stingl, M. Turpeinen, R. B. Altman, and T. E. Klein, “PharmGKB summary: venlafaxine pathway.,” Pharmacogenetics and Genomics, vol. 24, no. 1, pp. 62–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. H. Veefkind, P. M. J. Haffmans, and E. Hoencamp, “Venlafaxine serum levels and CYP2D6 genotype,” Therapeutic Drug Monitoring, vol. 22, no. 2, pp. 202–208, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. E. M. Whyte, M. Romkes, B. H. Mulsant et al., “CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly,” International Journal of Geriatric Psychiatry, vol. 21, no. 6, pp. 542–549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Hermann, M. Hendset, K. Fosaas, M. Hjerpset, and H. Refsum, “Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3,*4 or*5 allele,” European Journal of Clinical Pharmacology, vol. 64, no. 5, pp. 483–487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Jornil, T. S. Nielsen, I. Rosendal et al., “A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine,” Forensic Science International, vol. 226, no. 1-3, pp. e26–e31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Lessard, M.-A. Yessine, B. A. Hamelin, G. O'Hara, J. LeBlanc, and J. Turgeon, “Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans,” Pharmacogenetics, vol. 9, no. 4, pp. 435–443, 1999. View at Google Scholar · View at Scopus
  13. M. Vinetti, V. Haufroid, A. Capron, J.-F. Classen, S. Marchandise, and P. Hantson, “Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms,” Clinical Toxicology, vol. 49, no. 9, pp. 865–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. G. Laoutidis and K. T. Kioulos, “Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis,” Pharmacopsychiatry, vol. 48, no. 6, pp. 187–199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. B. A. Sproule, M. Hazra, and B. G. Pollock, “Desvenlafaxine succinate for major depressive disorder,” Drugs of Today, vol. 44, no. 7, pp. 475–487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Karlsson, A.-L. Zackrisson, M. Josefsson, B. Carlsson, H. Green, and F. C. Kugelberg, “Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases,” The Pharmacogenomics Journal, vol. 15, no. 2, pp. 165–171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Swen, M. Nijenhuis, A. de Boer et al., “Pharmacogenetics: from bench to byte—an update of guidelines,” Clinical Pharmacology & Therapeutics, vol. 89, no. 5, pp. 662–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. C. Shelton, “Steps following attainment of remission: Discontinuation of antidepressant therapy,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 3, no. 4, pp. 168–174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. S. V. Otton, S. E. Ball, S. W. Cheung, T. Inaba, R. L. Rudolph, and E. M. Sellers, “Venlafaxine oxidation in vitro is catalysed by CYP2D6,” British Journal of Clinical Pharmacology, vol. 41, no. 2, pp. 149–156, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. S. M. Fogelman, J. Ü. Schmider, K. Venkatakrishnan et al., “O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants,” Neuropsychopharmacology, vol. 20, no. 5, pp. 480–490, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Klamerus, K. Moloney, R. L. Rudolph, S. F. Sisenwine, W. J. Jusko, and S. T. Chiang, “Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite,” The Journal of Clinical Pharmacology, vol. 32, no. 8, pp. 716–724, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Charlier, E. Pinto, M. Ansseau, and G. Plomteux, “Venlafaxine: The relationship between dose, plasma concentration and clinical response in depressive patients,” Journal of Psychopharmacology, vol. 16, no. 4, pp. 369–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Howell, G. E. M. Husbands, J. A. Scatina, and S. F. Sisenwine, “Metabolic disposition of 14c-venlafaxine in mouse, rat, dog, rhesus monkey and man,” Xenobiotica, vol. 23, no. 4, pp. 349–359, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. EFFEXOR - venlafaxine hydrochloride [package insert]. Wyeth Pharmaceuticals Inc. , Philadelphia, PA, 2017.
  25. M. E. E. Shams, B. Arneth, C. Hiemke et al., “CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 5, pp. 493–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Bertilsson, M.-L. Dahl, P. Dalén, and A. Al-Shurbaji, “Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs,” British Journal of Clinical Pharmacology, vol. 53, no. 2, pp. 111–122, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. C. A. Kelly, N. Dhaun, W. J. Laing, F. E. Strachan, A. M. Good, and D. N. Bateman, “Comparative Toxicity of Citalopram and the Newer Antidepressants after Overdose,” Journal of Toxicology - Clinical Toxicology, vol. 42, no. 1, pp. 67–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. N. Johnson and M. J. Ackerman, “QTc: How long is too long?” British Journal of Sports Medicine, vol. 43, no. 9, pp. 657–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Adalimumab [package insert]. Abbott Laboratories, North Chicago, I, 2011.
  30. Lamictal [package insert]. GlaxoSmithKline . Research Triangle Park, NC, 2015.
  31. V. Law, C. Knox, Y. Djoumbou et al., “DrugBank 4.0: shedding new light on drug metabolism,” Nucleic Acids Research, vol. 42, no. 1, pp. D1091–D1097, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Khan, G. V. Upton, R. L. Rudolph et al., “The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study,” Journal of Clinical Psychopharmacology, vol. 18, no. 1, pp. 19–25, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz, “Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials,” The American Journal of Psychiatry, vol. 164, no. 2, pp. 290–300, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. L. B. Clau, M. Á. M. Gómez, P. V. Adán, M. M. Letosa, R. B. López, and F. G. López, “Hypersensitivity pneumonitis due to venlafaxine,” Archivos de Bronconeumología, vol. 44, no. 10, pp. 571–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Durand, G. Deplanque, V. Montheil et al., “Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial,” Annals of Oncology, vol. 23, no. 1, Article ID mdr045, pp. 200–205, 2012. View at Publisher · View at Google Scholar · View at Scopus